John Trizzino, Executive Vice President, Chief Commercial Officer, and Chief Business Officer of Novavax, joined Good Day BIO Live at the BIO International Convention, where he shared the company’s journey to creating a successful COVID vaccine.
Though the company was not 100% certain about the success before phase 1-2 trial in Australia began, Trizzino said Novavax saw signs the vaccine would be good, since they have previous experience with coronaviruses SARS and MERS.
While the recombinant protein nanoparticle was a great foundational element, it was the early investment the company received from CEPI, and later a $1.6 billion from the US government, that helped the vaccine development and trials run smoothly and at an accelerated pace.
Good Day BIO Live host Tetiana Anderson asked him whether it could be possible to develop the next vaccine in 100 days – and he said it’s “extraordinarily possible.”
“Good ideas are only as good as their execution, so 100 days is a great idea but you have to be prepared for that,” said John Trizzino, adding that manufacturing, regulatory support, and prior experience with similar infectious diseases are some of the basic elements necessary to embark on that journey.
Today, @jtrizzino stopped by #GoodDayBIO at @BIOconvention. See what he had to say: pic.twitter.com/tjzd3Mldg5
— Novavax (@Novavax) June 15, 2022
More Reading: Experts on lessons from COVID on manufacturing, distribution, and regulation
